H. Burstein

发表

Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.

S. Edge, A. Giuliano, L. Newman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.

E. Winer, R. Wahl, S. Edge, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

H. Burstein, D. Schrag, 2017, JAMA.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

J. Cuzick, A. Tutt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, Amy Sitapati, Andres Forero, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast cancer version 2.2015: Clinical practice guidelines in oncology

Benjamin O. Anderson, Matthew Philip Goetz, Lee S. Schwartzberg, 2015 .

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Donald A Berry, D. Berry, A. Gown, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant hormonal therapy for early-stage breast cancer.

J. Griggs, H. Burstein, 2010, Surgical oncology clinics of North America.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

E. Winer, K. Kuntz, H. Burstein, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Matthew P. Goetz, Sarah L. Blair, Kimberly H. Allison, 2019 .

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

E. Winer, H. Burstein, A. Partridge, 2001, Journal of the National Cancer Institute. Monographs.

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer

E. Winer, K. Kuntz, H. Burstein, 2006, Cancer.

Follow-up care of breast cancer survivors.

E. Winer, H. Burstein, A. Partridge, 2003, Seminars in oncology.

Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.

H. Burstein, 2003, The New England journal of medicine.

Treatment of breast cancer during pregnancy

H. Burstein, A. Partridge, B. Lesnikoski, 2002, Expert opinion on pharmacotherapy.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

E. Winer, S. Edge, T. Powles, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COVID-19 Pandemic Breast Cancer Consortium’s Considerations for Re-entry

Barbara L. Smith, M. Specht, W. Gradishar, 2020 .

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

W. Gradishar, H. Nelson, H. Burstein, 2020, Breast Cancer Research and Treatment.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

B. Ljung, E. Winer, E. Perez, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer, Version 3.2013

B. Ljung, D. Mankoff, S. Edge, 2013 .

Breast cancer version 3.2014.

B. Ljung, C. Hudis, W. Gradishar, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

HER2 overexpressing metastatic breast cancer

H. Burstein, D. Spigel, 2002, Current Treatment Options in Oncology.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.

J. Griggs, H. Burstein, C. Lacchetti, 2016, Journal of oncology practice.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

J. Griggs, E. Winer, C. Hudis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

With better adjuvant therapy, does breast cancer stage still matter?

H. Burstein, I. Vaz-Luis, 2015, BMJ : British Medical Journal.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

E. Winer, H. Burstein, J. Weeks, 2008, Journal of the National Cancer Institute.

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

E. Winer, H. Burstein, J. Weeks, 2008 .

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Susan M. Chang, A. M. López, R. Schilsky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast Cancer

B. Ljung, E. Winer, S. Edge, 2023, M.D. Anderson Solid Tumor Oncology Series.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, E. Perez, 2014, The New England journal of medicine.

Adjuvant ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, The New England journal of medicine.

Invasive breast cancer version 1.2016

C. Hudis, W. Gradishar, Rashmi Kumar, 2016 .

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

C. Hudis, W. Gradishar, Rashmi Kumar, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Lymphopenia associated with adjuvant anthracycline/ taxane regimens.

E. Winer, H. Burstein, S. Tolaney, 2008, Clinical breast cancer.

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.

E. Winer, H. Burstein, A. Partridge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Caring for breast cancer survivors.

H. Burstein, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Gemcitabine-induced radiation recall.

P. Wen, P. Jänne, R. Salgia, 2002, International journal of radiation oncology, biology, physics.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

E. Winer, J. Cuzick, A. Tutt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

P. Neven, R. Gelber, A. Goldhirsch, 2018, The Lancet. Oncology.

Preliminary Summary of the Consensus Discussion

J. Forbes, R. Gelber, H. Burstein, 2013 .

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

E. Winer, R. Gelber, S. Martino, 2018, The New England journal of medicine.

Postmenopausal breast cancer: a best endocrine strategy?

H. Burstein, E. Mayer, 2015, The Lancet.

Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po

R. Gelber, H. Burstein, M. Regan, 2015 .

Circulating Tumor Cells in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab and Chemotherapy

P. Friedman, L. Harris, K. Blackwell, 2009 .

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

P. Friedman, L. Harris, K. Blackwell, 2009, The International journal of biological markers.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Amy M. Sitapati, W. Gradishar, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer.

H. Burstein, I. Vaz-Luis, 2016, JAMA oncology.

Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy.

H. Burstein, M. Morrow, 2015, The New England journal of medicine.

Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)

E. Winer, C. Hudis, L. Carey, 2021, JNCI cancer spectrum.

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.

E. Winer, T. Fehm, C. Hudis, 2020, Journal of the National Cancer Institute.

Unmet challenges in systemic therapy for early stage breast cancer

H. Burstein, 2021, Breast.

NCCN Task Force Report : Positron Emission Tomography ( PET ) / Computed Tomography ( CT ) Scanning in Cancer

R. Coleman, R. Advani, A. Zelenetz, 2007 .

JNCCN NCCN Task Force Report : PET / CT Scanning in Cancer

R. Coleman, R. Advani, A. Zelenetz, 2007 .

Quality of non-breast cancer health maintenance among elderly breast cancer survivors.

E. Winer, C. Earle, H. Burstein, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality o f N on-Breast C ancer H ealth M aintenance A mong Elderly B reast C ancer S urvivors

E. Winer, C. Earle, H. Burstein, 2003 .

Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.

E. Winer, N. Lin, H. Burstein, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.

H. Burstein, 2011, Seminars in oncology.

Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes

H. Burstein, H. Li, M. Hassett, 2020, Breast Cancer Research and Treatment.

The global landscape of treatment standards for breast cancer.

E. Winer, W. Gradishar, L. Carey, 2021, Journal of the National Cancer Institute.

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

T. Choueiri, H. Burstein, J. Rosenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, W. Gradishar, R. Aft, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer, Version 3.2022

Amy M. Sitapati, W. Gradishar, R. Aft, 2022 .

Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes

H. Burstein, E. Mittendorf, T. King, 2022, Annals of Surgical Oncology.

Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.

E. Winer, R. Gelman, L. Parker, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

E. Winer, R. Gelman, H. Burstein, 2012, Breast Cancer Research and Treatment.

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer

E. Winer, R. Gelman, N. Lin, 2013, Breast Cancer Research and Treatment.

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

H. Burstein, C. Fabian, H. Parmar, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

R. Greil, E. Winer, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

A. D. Van den Abbeele, E. Winer, Minetta C. Liu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

H. Burstein, S. Wander, E. Mayer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted Therapy for Breast Cancer

H. Burstein, 2015 .

High performance teamwork training and systems redesign in outpatient oncology

E. Winer, M. Salisbury, H. Burstein, 2013, BMJ quality & safety.

Circulating Tumor Cells in Breast Cancer: Fiction or Reality?

C. Hudis, H. Burstein, E. Mayer, 2008 .

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

J. Baselga, G. Sledge, K. Blackwell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.

H. Burstein, D. Spigel, 2003, Clinical breast cancer.

G. Abel, H. Burstein, N. Hevelone, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient advocates' role in clinical trials

R. Schilsky, H. Burstein, D. Collyar, 2012, Cancer.

Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary.

H. Rugo, H. Burstein, R. B. Rumble, 2016, Journal of oncology practice.

Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.

E. Winer, J. Bellon, R. Gelman, 2006, International journal of radiation oncology, biology, physics.

A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma.

E. Winer, W. Barry, H. Rugo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

E. Winer, L. Trippa, N. Lin, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

H. Burstein, E. Mayer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

E. Winer, E. Perez, G. Hortobagyi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.

H. Burstein, 2006, Oncology.

Chemotherapy for metastatic breast cancer.

H. Burstein, E. Mayer, 2007, Hematology/oncology clinics of North America.

American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

J. Griggs, S. Temin, H. Burstein, 2010, Journal of oncology practice.

Activation and Functions of CD4+ T‐Cell Subsets

P. Bossù, H. Burstein, A. Abbas, 1991, Immunological reviews.

Session 11: Adjuvant systemic treatment for the individual patient I: Endocrine therapies: New aspects for old treatments

H. Burstein, N. Davidson, 2015 .

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

E. Winer, C. Denkert, M. Gnant, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Unmet challenges in systemic therapy for early stage breast cancer

H. Burstein, 2021, Breast.

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Erin M. Olson, E. Winer, N. Lin, 2013, Breast.

Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.

E. Winer, H. Burstein, S. Joffe, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab in Combination with Chemotherapy

H. Burstein, 2003, Breast Cancer Research and Treatment.

Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer

M. Ellis, L. Carey, H. Rugo, 2017 .

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

J. Griggs, E. Winer, C. Hudis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.

J. Baselga, M. Casey, S. Stein, 2009 .

Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age.

H. Burstein, 2009, Breast.

Beaten at the Alamo by the Europeans.

H. Burstein, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

J. Beckman, H. Burstein, S. Dallabrida, 2011, Hypertension.

Do patients participating in clinical trials want to know study results?

E. Winer, R. Gelman, H. Burstein, 2003, Journal of the National Cancer Institute.

Docetaxel administered on a weekly basis for metastatic breast cancer.

J. Manola, E. Winer, L. Parker, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".

M. Gnant, H. Burstein, S. Loibl, 2019 .

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

E. Winer, R. Gelber, L. Trippa, 2022, NPJ breast cancer.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer

H. Burstein, N. Harbeck, S. Johnston, 2022, Cancer.

Postneoadjuvant treatment for triple-negative breast cancer

H. Burstein, G. Curigliano, D. Trapani, 2022, Current opinion in oncology.

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

E. Winer, S. Schnitt, H. Rugo, 2021, Annals of Oncology.

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.

H. Burstein, H. Parsons, 2020, JAMA.

The Legacy of Professor Aron Goldhirsch.

E. Winer, R. Gelber, M. Piccart, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

M. Ellis, E. Winer, C. Hudis, 2015, Breast Cancer Research and Treatment.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

H. Rugo, A. Wolff, H. Burstein, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.

E. Winer, L. Harris, H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine.

H. Burstein, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit.

H. Burstein, 2019, Breast.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

R. Schilsky, J. Heymach, J. D. de Groot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

E. Winer, L. Trippa, R. Bose, 2020 .

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

E. Winer, N. Lin, H. Burstein, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

E. Winer, S. Edge, T. Powles, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

E. Winer, D. Lake, W. Barry, 2010 .

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

E. Perez, R. Gelber, S. Martino, 2014, Journal of Clinical Oncology.

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

H. Burstein, 2020, The New England journal of medicine.

E. Winer, Minetta C. Liu, R. Bose, 2021, Breast Cancer Research and Treatment.

Commentary on “Internet Usage Among Women with Breast Cancer: An Exploratory Study”

H. Burstein, 2000 .

H. Burstein, E. Mittendorf, T. King, 2022, Annals of Surgical Oncology.

Update in Hematology and Oncology: Evidence Published in 2015

H. Burstein, A. Ma, 2016, Annals of Internal Medicine.

Patients with anti-HER2 responsive disease: definition and adjuvant therapies.

H. Burstein, 2011, Breast.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

James N Ingle, E. Winer, T. Powles, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.

E. Winer, H. Burstein, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.

C. Hudis, J. Garber, H. Burstein, 2006, Clinical breast cancer.

Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

G. Hortobagyi, A. Giuliano, S. Shak, 2022, Annals of Surgical Oncology.

Molecular Testing in Breast Cancer.

H. Burstein, N. Turner, J. Litton, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Breast cancer. Clinical practice guidelines in oncology.

Krystyna Kiel, Mohammad Jahanzeb, Ingrid A Mayer, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Invasive breast cancer.

Richard Zellars, Andres Forero, David A Mankoff, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Reply to S. Mahesh

E. Winer, E. Perez, G. Hortobagyi, 2012 .

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

Lyndsay Harris, Donald Berry, Larry Norton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Lesley Fallowfield, Mohammad Jahanzeb, Debra L Barton, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Past, present, and future challenges in breast cancer treatment.

G. Hortobagyi, G. Sledge, A. Wolff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

E. Winer, L. Carey, W. Barry, 2013 .

Determinants of helper T cell-dependent antibody production.

H. Burstein, A. Abbas, S. Bogen, 1993, Seminars in immunology.

Novel agents and future directions for refractory breast cancer.

H. Burstein, 2011, Seminars in oncology.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

E. Winer, H. Burstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen

H. Burstein, A. Abbas, Abul K. Abbas, 1993, The Journal of experimental medicine.

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

C. Hudis, W. Gradishar, Rashmi Kumar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

How Old is Too Old? Breast Cancer Treatment in Octogenarians

H. Burstein, P. Exman, 2018, Annals of Surgical Oncology.

T-cell-mediated activation of B cells.

H. Burstein, A. Abbas, 1991, Current opinion in immunology.

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

E. Winer, R. Gelman, L. Parker, 2007, Investigational New Drugs.

'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.

H. Burstein, E. Mittendorf, E. Mayer, 2022, Journal of geriatric oncology.

Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments?

H. Burstein, Y. Yeh, P. Reddy, 2015, Journal of oncology practice.

A "shot heard 'round the world" on cancer drug costs?

H. Burstein, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer—Translational Therapeutic Strategies

G. Lyman, H. Burstein, 2007 .

Adjuvant endocrine therapy for postmenopausal women: Type and duration.

H. Burstein, E. Mayer, 2015, Breast.

Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells.

H. Burstein, A. Abbas, C. Shea, 1992, Journal of immunology.

EMBRACE, eribulin, and new realities of advanced breast cancer

N. Lin, H. Burstein, 2011, The Lancet.

Radiation therapy for ductal carcinoma in situ

H. Burstein, J. Weeks, R. Punglia, 2012, Cancer.

Breast Cancer—Translational Therapeutic Strategies

G. Lyman, H. Burstein, 2007 .

Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates?

Barbara L. Smith, E. Winer, J. Bellon, 2012, The breast journal.

Off-label use of oncology drugs: too much, too little, or just right?

H. Burstein, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with triple negative breast cancer: is there an optimal adjuvant treatment?

H. Burstein, 2013, Breast.

Molecular origins of cancer.

R. Schwartz, H. Burstein, 2008, The New England journal of medicine.

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)

H. Rugo, H. Burstein, M. Collier, 2005 .

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

E. Winer, R. Gelman, H. Burstein, 2013, Breast Cancer Research and Treatment.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

V. Valero, A. Wolff, H. Burstein, 2022, npj Breast Cancer.

Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer

E. Winer, L. Trippa, N. Lin, 2021, The oncologist.

Primary care for survivors of breast cancer.

E. Winer, H. Burstein, Eric P. Winer, 2000, The New England journal of medicine.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

B. Ljung, D. Mankoff, S. Edge, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Amy M. Sitapati, B. Ljung, D. Mankoff, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer

E. Winer, H. Burstein, M. Koehler, 2018 .

Ductal Carcinoma in Situ of the Breast

Kornelia Polyak, K. Polyak, H. Burstein, 2004, Strahlentherapie und Onkologie.

New Combinations with Herceptin® in Metastatic Breast Cancer

E. Winer, H. Burstein, 2001, Oncology.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Yan Sun, Luc Y Dirix, Zefei Jiang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

E. Rutgers, M. Piccart, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

S. Cummings, E. Winer, R. Chlebowski, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

M. Ellis, E. Winer, C. Hudis, 2015, The New England journal of medicine.

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

S. Franco, S. Stein, K. Blackwell, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

J. Baselga, M. Casey, G. Sledge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

E. Winer, P. Friedman, D. Sgroi, 2007, Clinical Cancer Research.

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

Barbara L. Smith, E. Winer, R. Gelman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, W. Gradishar, R. Aft, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

E. Winer, S. Edge, R. Theriault, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer: noninvasive and special situations.

B. Ljung, E. Winer, S. Edge, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Second consensus on medical treatment of metastatic breast cancer.

M. Stockler, M. Gnant, H. Burstein, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

NCCN Task Force Report: mTOR inhibition in solid tumors.

P. Febbo, D. Ettinger, R. Figlin, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of alternative medicine by women with early-stage breast cancer.

E. Guadagnoli, H. Burstein, J. Weeks, 1999, The New England journal of medicine.

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.

J. Baselga, H. Burstein, P. Fumoleau, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

The distinctive nature of HER2-positive breast cancers.

H. Burstein, Harold J Burstein, 2005, The New England journal of medicine.

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

E. Winer, M. Rue, R. Gelman, 2003, Cancer.

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.

M. Somerfield, J. Ajani, H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN task force report: management of neuropathy in cancer.

Sudhakar Tummala, Larry Junck, J. V. Von Roenn, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Hormone Replacement Therapy after Breast Cancer?

H. Burstein, 2003, Breast Cancer Research and Treatment.

Humoral immune functions in IL-4 transgenic mice.

P. Leder, H. Burstein, A. Abbas, 1991, Journal of immunology.

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

M. Somerfield, L. Fallowfield, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?

H. Burstein, G. Viale, C. Criscitiello, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

Giuseppe Curigliano, E. Winer, A. Goldhirsch, 2010, Progress in cardiovascular diseases.

Invasive Breast CancerPractice Guidelines in Oncology

B. Ljung, D. Mankoff, S. Edge, 2011 .

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

N. Lin, H. Burstein, E. Mayer, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Jerry Younger, Lyndsay N Harris, Judy E Garber, 2008, Clinical Cancer Research.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

J. Griggs, E. Winer, M. Somerfield, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Endocrine Therapy

H. Burstein, 2010 .

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

A. Giobbie-Hurder, N. Lin, H. Burstein, 2020, Breast Cancer Research and Treatment.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, C. Hudis, L. Carey, 2023, The New England journal of medicine.

Aromatase inhibitor-associated arthralgia syndrome.

H. Burstein, 2007, Breast.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Richard L Schilsky, Michael N Neuss, Howard A Fine, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

J. Baselga, G. Sledge, K. Blackwell, 2008 .

Peek before you treat? Is it a fantasy or reality?

J. Ajani, H. Burstein, P. Mangu, 2011, Journal of oncology practice.

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

M. Somerfield, H. Burstein, H. Garewal, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

E. Winer, P. Morris, H. Rugo, 2021, The Lancet. Oncology.

Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.

E. Winer, C. Denkert, M. Gnant, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

M. Gnant, H. Burstein, S. Loibl, 2020 .

Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium.

E. Perez, C. Hudis, H. Burstein, 2011, Clinical advances in hematology & oncology : H&O.

Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).

D. Berry, E. Winer, C. Hudis, 2015 .

Breast Cancer Version 2.2015.

Andres Forero, Hatem Soliman, Rashmi Kumar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

E. Winer, R. Gelman, L. Harris, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.

E. Winer, G. Hortobagyi, A. Giuliano, 2021, Journal of the National Cancer Institute.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

D. Berry, E. Winer, C. Hudis, 2016, Breast Cancer Research and Treatment.

Surgery of the primary tumor does not improve survival in stage IV breast cancer

J. Niland, S. Edge, H. Burstein, 2011, Breast Cancer Research and Treatment.

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival

Barbara L. Smith, Mehra Golshan, Eric P. Winer, 2009, Breast Cancer Research and Treatment.

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

J. Manola, E. Winer, R. Gelman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations

B. Ljung, E. Winer, E. Perez, 2006 .

Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

H. Bartelink, L. Pusztai, J. Reis-Filho, 2012, The breast journal.

Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.

D. Sgroi, H. Burstein, I. Souter, 2009, The New England journal of medicine.

Adjuvant chemotherapy in older women with early-stage breast cancer.

H. Cohen, D. Berry, E. Winer, 2009, The New England journal of medicine.

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

R. Gelber, A. Goldhirsch, J. Bernhard, 2015, The Lancet. Oncology.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

Vered Stearns, J. Griggs, E. Winer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

M. Arbushites, S. Stein, K. Blackwell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

E. Winer, H. Burstein, P. Klein, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

E. Winer, D. Lake, M. Gnant, 2022, Journal of Clinical Oncology.

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.

Erin M. Olson, E. Winer, N. Lin, 2013, Clinical breast cancer.

Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

M. Ellis, E. Winer, C. Hudis, 2019, Breast Cancer Research and Treatment.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lauren L. Ritterhouse, E. Winer, C. Hudis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

J. Baselga, K. Blackwell, H. Burstein, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

E. Winer, R. Gelman, H. Burstein, 2007, Cancer.

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.

E. Winer, W. Barry, H. Rugo, 2019 .

New cytotoxic agents and schedules for advanced breast cancer.

E. Winer, H. Burstein, C. Bunnell, 2001, Seminars in oncology.

Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region

M. Dwyer, Rashmi Kumar, H. Burstein, 2010 .

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

J. Griggs, H. Burstein, C. Lacchetti, 2019, Journal of oncology practice.

Standards for follow-up care of patents with breast cancer.

E. Winer, H. Burstein, A. Partridge, 2005, Breast.

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer

A. Wolff, H. Burstein, J. Mandelblatt, 2019, Journal of the American Geriatrics Society.

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

S. Franco, S. Stein, K. Blackwell, 2008, Annals of Oncology.

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea

E. Winer, D. Lake, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

E. Winer, R. Gelman, L. Harris, 2009, Breast Cancer Research and Treatment.

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab

E. Winer, N. Keating, W. Barry, 2016, Breast Cancer Research and Treatment.

Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study

J. Gagne, H. Burstein, I. Braun, 2017, Psycho-oncology.

Practice Patterns, Guideline-Based Treatments, Costs and Efficacy of Care, and Global Perspectives: A Call for Papers on Excellence in Cancer Care

H. Burstein, 2010 .

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

E. Winer, E. Perez, C. Hudis, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

On Sequencing the Full Genome of a Cancerous Cell

H. Burstein, 2009 .

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

A. Giobbie-Hurder, R. Gelber, A. Goldhirsch, 2020, Breast Cancer Research and Treatment.

Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.

E. Winer, L. Parker, H. Burstein, 2015, Clinical breast cancer.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

E. Winer, G. Hortobagyi, Baljit Singh, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus on Medical Treatment of Metastatic Breast Cancer

M. Stockler, H. Burstein, J. Bonneterre, 2003, Breast Cancer Research and Treatment.

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.

H. Cohen, D. Berry, E. Winer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

M. Ellis, E. Winer, C. Hudis, 2016, JAMA oncology.

CMF revisited in the 21st century.

E. Winer, A. Goldhirsch, H. Burstein, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical A ctivity o f T rastuzumab a nd V inorelbine i n Women W ith H ER2-Overexpress ing M etastatic B reast Cancer

J. Manola, E. Winer, R. Gelman, 2001 .

HER2 or not HER2: that is the question.

E. Winer, H. Burstein, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discussing complementary therapies with cancer patients: what should we be talking about?

H. Burstein, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer

Darrell N. Smith, E. Winer, J. Bellon, 2003 .

Herceptin and vinorelbine for HER2-positive metastatic breast cancer : a phase II study

H. Burstein, 2000 .

Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

E. Winer, A. DeMichele, H. Burstein, 2018 .

Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).

M. Ellis, E. Winer, C. Hudis, 2017 .

JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines

E. Winer, E. Perez, C. Hudis, 2006 .

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

E. Winer, R. Gelber, S. Loi, 2022, Cancer Research.

NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology

Amy M. Sitapati, B. Ljung, C. Hudis, 2014 .

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

T. Golub, L. Carey, A. Wolff, 2023, medRxiv.

The role of angiogenesis inhibition in the treatment of breast cancer.

G. Sledge, H. Rugo, H. Burstein, 2006, Clinical advances in hematology & oncology : H&O.

NCCN Task Force Report: breast cancer in the older woman.

E. Winer, W. Gradishar, R. Carlson, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

E. Winer, J. Cuzick, J. Bergh, 2017 .

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Amy M. Sitapati, Amy Sitapati, Chau Dang, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™

Lawrence B. Marks, Robert W. Carlson, Daniel F. Hayes, 2007 .

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

M M Regan, S Loibl, M. Gnant, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer

E. Winer, J. Bellon, H. Burstein, 2022, International Journal of Radiation Oncology, Biology, Physics.

Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy

H. Burstein, 2007 .

Original article Cognitive side-effects of adjuvant treatments

H. Burstein, 2007 .

Cognitive side-effects of adjuvant treatments.

H. Burstein, 2007, Breast.

TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.

E. Winer, L. Carey, R. Gelman, 2010 .

Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer

M. Berger, H. Burstein, N. Spector, 2005 .

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

B. Spiegelman, E. Winer, G. Demetri, 2003, Breast Cancer Research and Treatment.

Making genuine progress against metastatic breast cancer.

R. D'Agostino, P. Ellis, A. Buzdar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidisciplinary considerations in the treatment of triple‐negative breast cancer

J. Bellon, H. Burstein, E. Mittendorf, 2020, CA: a cancer journal for clinicians.

Predicting the Risk of Axillary Nodal Metastases and Their Use in Selecting Breast Surgery Options

E. Winer, H. Burstein, 2009 .

Invasive breast cancer.

B. Ljung, E. Winer, S. Edge, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.

J. Griggs, H. Burstein, Harold J Burstein, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avastin for breast cancer, 2005-2011: requiescat in pacem?

H. Burstein, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Cardiovascular safety of adjuvant bevacizumab for breast cancer.

E. Winer, L. Carey, R. Gelman, 2010 .

Breast cancer: Neoadjuvant bevacizumab treatment—signal or noise?

H. Burstein, 2012, Nature Reviews Clinical Oncology.

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

H. Burstein, S. Tolaney, A. Grinshpun, 2023, npj Breast Cancer.

Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.

H. Burstein, E. Mayer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Therapy as a Model for Translational Research in Breast Cancer

H. Burstein, 2008, Cancer investigation.

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

E. Ziv, H. Burstein, A. Wu, 2012, Breast Cancer Research and Treatment.

Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors

E. Winer, K. Kuntz, H. Burstein, 2005 .

ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

E. Provenzano, L. Carey, A. Vincent-Salomon, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Duration of adjuvant trastuzumab: might less be more?

H. Burstein, O. Metzger Filho, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of Doxil and vinorelbine in metastatic breast cancer.

E. Winer, M. Warmuth, L. Parker, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making.

E. Winer, H. Burstein, A. Richardson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance and Reimbursement

N. Lin, H. Burstein, J. Brock, 2023, JCO oncology practice.

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

L. Carey, H. Burstein, E. Mayer, 2007, Breast Cancer Research.

Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.

E. Winer, W. Barry, H. Burstein, 2014 .

Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study

E. Winer, R. Gelman, L. Parker, 2007 .

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

W. Gradishar, R. Aft, M. Dwyer, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ.

H. Burstein, J. Weeks, J. Wong, 2010 .

Avastin, ODAC, and the FDA: are we drafting the right players?

H. Burstein, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Pathway-based oncology care: time for more transparency.

H. Burstein, 2012, The Journal of the National Comprehensive Cancer Network.

Mind the gap.

H. Burstein, 2011, The Journal of the National Comprehensive Cancer Network.

Pathologic Complete Response with Docetaxel Neoadjuvant Therapy for Breast Cancer

H. Burstein, J. O’Shaughnessy, V. Jain, 2003 .

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Amy M. Sitapati, W. Gradishar, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer

M. Piccart, M. Gnant, A. DeMichele, 2017 .

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.

M. Somerfield, J. Ajani, H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.

T. Golub, L. Carey, A. Wolff, 2023, Annals of Oncology.

Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy.

Annette S. Kim, H. Burstein, E. Mittendorf, 2023, Journal of the National Cancer Institute.

Invasive breast cancer.

B. Ljung, D. Mankoff, S. Edge, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Third consensus on medical treatment of metastatic breast cancer.

M. Stockler, M. Gnant, H. Burstein, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

J. Griggs, M. Somerfield, C. Hudis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

A. DeMichele, H. Burstein, M. Regan, 2023, Cancer Research.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

B. Ljung, D. Mankoff, S. Edge, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Featured Updates to the NCCN Guidelines

Amy M. Sitapati, W. Gradishar, Rashmi Kumar, 2015 .

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

J. Beckman, H. Burstein, S. Dallabrida, 2011, HYPERTENSION.

Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer?

J. Bellon, H. Burstein, J. Wong, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Amy M. Sitapati, W. Gradishar, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

H. Burstein, D. Spigel, N. Tayob, 2023, Breast cancer research and treatment.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

H. Burstein, Anthony D. Elias, Kimberly H. Allison, 2019 .

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

M. Somerfield, A. DeMichele, H. Burstein, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer. Clinical practice guidelines in oncology.

B. Ljung, C. Hudis, W. Gradishar, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.

J. Griggs, H. Burstein, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

M. Ellis, C. Hudis, L. Carey, 2023, The Lancet. Oncology.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Amy M. Sitapati, W. Gradishar, R. Aft, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, E. Winer, C. Hudis, 2015, The New England journal of medicine.

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

E. Winer, D. Lake, M. Gnant, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The top five in oncology: where do we go from here?

H. Burstein, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant Endocrine Therapy

H. Burstein, 2010 .

NCCN Task Force Report: mTOR inhibition in solid tumors.

P. Febbo, D. Ettinger, R. Figlin, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

G. Hortobagyi, A. Giuliano, S. Shak, 2022, Annals of Surgical Oncology.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

E. Winer, R. Schilsky, C. Hudis, 2011, European journal of cancer.

Personalized medicine and breast cancer care.

H. Burstein, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.